Section 8, Obesity Management for the Treatment of Type 2 Diabetes, of the Standards of Medical Care in Diabetes—2020 has been annotated based on a U.S. Food and Drug Administration Drug Safety Communication.
The online version of the article (https://doi.org/10.2337/dc20-S008) reflects the changes described below.
Updates have been made to the “Approved Weight-Loss Medications” subsection (p. S92).
The following sentence was revised to change “Five” to “Four”:
“Four weight-loss medications are FDA approved for long-term use (more than a few weeks) by patients with BMI ≥27 kg/m2 with one or more obesity-associated comorbid condition (e.g., type 2 diabetes, hypertension, and/or dyslipidemia) who are motivated to lose weight (46).”
The following sentence was added:
“The FDA requested the withdrawal of weight-loss drug lorcaserin (U.S. Food and Drug Administration, 2020); it should no longer be used.”
“Lorcaserin” has been removed from Table 8.2.